Venture
Kriya Therapeutics, Inc.
Latest Form D 2025-09-10- CIK 1811209
- State NC
- Biotechnology
- 4 Form D offerings since 2020-05-19
- Total sold
- $870M
- across 4 offerings
- Rounds
- 4
- Form D offerings since 2020-05-19
- Latest round
- $321M
- 2025-08-15 · 021-554967
- Investors
- 10
- on the latest round
Connected
named in its Form D filingsRound timeline
amount sold · by first filed2025-08-15 · $321M
- 2020-05-19$87.6M021-367242
- 2021-07-14$100M021-406240
- 2022-05-24$362M021-446798
- 2025-08-15$321M021-554967
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($362M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-554967 | First filed2025-08-15 | Latest2025-09-10 | Sought$321M | Sold$321M | Investors10 | Exemptions506(b) |
| 021-446798 | First filed2022-05-24 | Latest2023-07-27 | Sought$432M | Sold$362M | Investors29 | Exemptions506(b) |
| 021-406240 | First filed2021-07-14 | Latest2021-07-14 | Sought$100M | Sold$100M | Investors36 | Exemptions506(b) |
| 021-367242 | First filed2020-05-19 | Latest2020-08-18 | Sought$87.6M | Sold$87.6M | Investors21 | Exemptions506(b) |
Who backs Kriya Therapeutics, Inc., inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2025-09-10
| Name | Relationship |
|---|---|
| Shankar Ramaswamy | RelationshipExecutive Officer, Director |
| Trit Garg | RelationshipDirector |
| Ryan Gallagher | RelationshipDirector |
| Roger Jeffs | RelationshipDirector |
| Keith Manchester | RelationshipDirector |
| James Momtazee | RelationshipDirector |
| Ilan Oren | RelationshipDirector |
| Akshay Rai | RelationshipDirector |
| Saira Ramasastry | RelationshipDirector |
| Neelaksh Varshney | RelationshipDirector |
| Curt Herberts | RelationshipExecutive Officer |
| Katherine Eade | RelationshipExecutive Officer |
| Brian Furmanski | RelationshipExecutive Officer |
| Britt Petty | RelationshipExecutive Officer |
| Michele Stone | RelationshipExecutive Officer |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- North Carolina (NC)
- Exemptions
- Rule 506(b)
- First filed
- 2020-05-19
- Latest filing
- 2025-09-10
Who backs Kriya Therapeutics, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗